Increased Expression of Cytoskeletal, Linkage, and Extracellular Proteins in Failing Human Myocardium
Jump to

Abstract
Abstract—Experimental studies have shown that in hypertrophy and heart failure, accumulation of microtubules occurs that impedes sarcomere motion and contributes to decreased ventricular compliance. We tested the hypothesis that these changes are present in the failing human heart and that an entire complex of structural components, including cytoskeletal, linkage, and extracellular proteins, are involved in causing functional deterioration. In explanted human hearts failing because of dilated cardiomyopathy (ejection fraction ≤20%), expression of α- and β-tubulin, desmin, vinculin, fibronectin, and vimentin was determined by Northern and Western blot analysis and compared with normal myocardium from explants not used for transplantation. The mRNA for α- and β-tubulin was increased to 2.4-fold (P<0.01) and 1.25-fold (NS), respectively; for desmin, 1.2-fold (P<0.05); for fibronectin, 5-fold (P<0.001); and for vimentin, 1.7-fold (P<0.05). Protein levels for α-tubulin increased 2.6-fold (P<0.02); for β-tubulin, 1.2-fold (P<0.005); for desmin, 2.1-fold (P<0.001); for vinculin, 1.2-fold (P<0.005); for fibronectin, 2.9-fold (P<0.001); and for vimentin, 1.5-fold (P<0.005). Confocal microscopy showed augmentation and disorganization of all proteins studied. In combination with the loss of myofilaments and sarcomeric skeleton previously reported, these changes suggest cardiomyocyte remodeling. Increased fibronectin and elevated interstitial cellularity (vimentin labeling) indicate progressive fibrosis. The present results suggest a causative role of cytoskeletal abnormalities and myofilament loss for intrinsic contractile and diastolic dysfunction in failing hearts.
End-stage human chronic heart failure is the common final manifestation of a group of different diseases (such as ischemic heart disease, hypertension, valve defects, dilated cardiomyopathy, and others), and it is usually accompanied by myocardial hypertrophy.1 Only a few animal models exist to study this pathophysiologic situation, and these usually are not able to mimic the slowly developing human situation. Therefore, most studies concerning the mechanism of reduced function are carried out in tissue samples from human hearts obtained at the time of cardiac transplantation, either from ischemic hearts or from those with dilated cardiomyopathy (DCM). In this study, we present data obtained in failing human hearts with DCM. In the late stages of this disease, numerous degenerative structural alterations of the cardiomyocytes, as well as areas of focal fibrosis, are scattered throughout the ventricular walls.2 3 4
Decompensated hypertrophy occurs when increased cardiac mass fails to normalize wall stress,5 and it has been postulated that in the transition of compensated hypertrophy to a decompensated state, the cardiomyocyte cytoskeleton plays a key role in causing contractile and diastolic dysfunction.6 7 8
Alterations of the cytoskeleton have been described in many excellent studies, by Tsutsui et al6 7 and Tagawa et al,8 9 10 11 in hypertrophied and failing right ventricles of feline6 7 9 10 11 and canine8 myocardium. It was shown that the increase in tubulin occurs at the mRNA as well as at the protein level and that an increased viscosity and stiffness of the cardiomyocytes is the consequence of increased amounts and abnormal polymerization of microtubules.11 Evidence was presented that increased microtubular density imposes an intracellular load on the cardiac myocyte that will result in impediment of sarcomere motion and contribute to decreased compliance of the hypertrophied myocardium. In another study, microtubule stabilization and the elevated expression of microtubule-associated protein-4 have been associated with contractile dysfunction.12 It was furthermore shown that accumulation of β-tubulin and contractile dysfunction may be related to the mechanical forces imposed on the myocardium during the onset and progression of pressure overload.13
The view that increased microtubular stabilization may be an important factor in causing cellular stiffness and contractile dysfunction in pressure-overload hypertrophy is shared by Wang et al.14 On the other hand, Collins et al,15 investigating cytoskeletal gene expression in a similar experimental model, found the opposite. The authors concluded that neither the level of β-tubulin nor its polymerization state affected the contractile performance of the overloaded left ventricle. The role of tubulin accumulation and polymerization was also questioned by Bailey et al,16 who failed to find an effect of colchicine on contraction dynamics in isolated feline myocytes from hypertrophied hearts, and by de Tombe,17 who studied the effects of colchicine and taxol on rat trabecula contractility.
In 1991, our group described accumulation and disorganization of microtubules and desmin filaments in human tissue with chronic heart failure.3 In continuation of this work, we tested the hypothesis and present here quantitative protein and mRNA data that show that an entire system of structural proteins, including the cytoskeleton and proteins linking the intracellular milieu to the extracellular matrix such as vinculin and fibronectin, are involved in causing the functional and structural deterioration characteristic of heart failure.
Materials and Methods
Nineteen patients with end-stage heart failure (ejection fraction ≤20%) due to DCM without any evidence of myocardial infarction undergoing heart transplantation were studied. Hearts from donors with normal left ventricular function not used for transplantation served as controls. The study was approved by the institutional ethical committee. All clinical data are presented in Table 1⇓.
Clinical Characteristics of the Patient Population
Tissue Sampling
At the time of transplantation, tissue was removed from the left ventricular free wall excluding papillary muscles. Up to 3 samples were used for either Western or Northern blot and 5 to 8 samples for confocal microscopy. Samples for Western blot were also examined by microscopy. Samples were immediately frozen in liquid nitrogen and stored at –80°C until further use.
Western Blot
All antibodies used for Western blot and immunofluorescence are listed in Table 2⇓.
Antibodies Used for Western Blotting (WB) and Immunofluorescence (IF)
SDS-PAGE (separating gels 12%) and immunoblotting were carried out following routine protocols. At least 2 different gels were prepared from each heart. For each lane, 30 μg of protein was loaded. Tissue samples from 3 donors served as control.
Quantification was done by densitometry either by using the gel-analyzing program Quantity One (Protein Imageware System) or by scanning the immunoblots on a STORM 860 imager (Amersham Pharmacia Biotech) using ImageQuant software. All data were expressed as mean±SEM. Statistical analysis by unpaired t test was considered significant when P<0.05.
Standardization
To exclude the possibility that the tubulin measured originated from an increased number of fibroblasts in fibrotic tissue, myocardium was first evaluated by light microscopy, and samples showing absence of fibrosis were selected. However, the contribution of an increased number of fibroblasts cannot be entirely excluded. Immunoblotting for pan-actin was performed, and only samples showing a similar density of the actin band at 42 kDa were used in this study. The total protein applied to the gel was kept constant.
Northern Blot
The following molecular probes were used for Northern blot analysis: human α- and β-tubulin and human vimentin (American Type Culture Collection), human desmin (R. Zimmermann, unpublished), rat fibronectin clone pRCabFN1 (K. Boheler, National Heart and Lung Institute, London, UK), and a murine 18S ribosomal RNA cDNA probe (a gift of I. Oberbäumer, Max-Planck-Institut, Mar-tinsried, Germany).
Standard methods for Northern blots were used.18 Each gel was done at least in duplicate to control for variability within and between gels. For each well, 15 μg of total RNA was loaded. Tissue samples from 3 donors served as control.
Quantification of mRNA levels was performed using a PhosphorImager and ImageQuant software (Molecular Dynamics). For normalization, the data of each hybridization signal were divided by the matching 18S signal. All data are presented as mean±SEM. Expression was assessed by an unpaired t test. Statistical significance was accepted as P<0.05.
Immunolabeling and Confocal Microscopy
From each left ventricle, 5 to 8 randomly chosen samples were prepared as previously described.19 Omission of primary antibodies served as negative controls. Preparations were viewed in a confocal laser microscope (Leica) equipped with appropriate filter blocks. The optical confocal sections taken through the depth of tissue samples at 0.5- to 1-μm intervals were viewed and photographed individually or were superimposed for reconstruction in a 3-dimensional mode using a Silicon Graphics Indy workstation and 3-dimensional multichannel image processing software (Bitplane).
Results
All proteins studied, with the exception of vimentin, are schematically represented in Figure 1⇓. Vimentin is present in fibroblasts and in endothelial cells.
Illustration of the localization of the proteins investigated. a, Isolated rat myocyte shows network-like longitudinally oriented localization of β-tubulin. b, Schematic representation of localization of desmin around the Z-disks of the sarcomeres. c, Localization of vinculin (Vc) as a link between the intracellular milieu and extracellular fibronectin via the integrins of the sarcolemma. Tubulin is present also in fibroblasts. Vimentin present in fibroblasts and endothelial cells is not shown here.
α- and β-Tubulin
Both the α- and β-tubulin isoforms showed an upregulation in the Northern blot, 2.4- and 1.25-fold respectively, and 2.6- and 1.2-fold in Western blot (Figures 2A⇓ through 2D). The immunocytochemical localization of α- and β-tubulin demonstrated an increased density of microtubules in most of the cardiomyocytes as compared with control tissue. Microtubules, normally visible as fine filamentous structures, were disorganized and aggregated, especially in the perinuclear area, ie, microtubular density was increased (Figures 2E⇓ and 2F⇓).
mRNA for α- and β-tubulin is significantly increased (A and C) as compared with control (con). Protein levels in failing hearts are elevated for both isoforms in the Western blot (B and D). Blots were carried out for all 19 failing hearts and the controls, but only representative lanes are shown in Figures 2⇓, 3⇓, 5⇓, 6⇓, and 7⇓. E and F, Immunofluorescence for α-tubulin (green). E, In normal myocardium, the myocytes are regularly arranged and the tubulin fluorescence is present as a fine network in each cell. F, In failing myocardium, the tubulin fluorescence is more dense and irregular in numerous cells as compared with panel E.
Desmin
Northern blot analysis exhibited a 1.2-fold increase of desmin mRNA (Figure 3A⇓), Western blot showed a 2.1-fold elevation (Figure 3B⇓).
Desmin is significantly increased on the mRNA and protein levels as shown by Northern (A) and Western (B) blot analysis (con indicates control). C and D, Confocal microscopy for desmin. C, Normal human myocardium shows a regular cross-striation at the Z-level and distinct intercalated disk labeling. D, In failing myocardium, the cross-striation pattern is disturbed and desmin is accumulated in many irregularly shaped cells. Nuclei are red.
In the confocal microscope, a distinct desmin cross-striation pattern is typical of normal myocytes (Figure 3C⇑). In failing myocardium, desmin was disorganized and accumulated in many cardiomyocytes (Figure 3D⇑).
A good correlation was found between the amount of cytoskeletal proteins (desmin and tubulin) and the left ventricular end-diastolic pressure (LVEDP) in controls and DCM patients (Figure 4⇓).
A good correlation exists between LVEDP and cytoskeletal protein content (tubulin and desmin).
Vinculin
As compared with normal myocardium, vinculin was 1.2-fold increased in patients with failing hearts in Western blot (Figure 5A⇓).
A, Immunoblotting shows that vinculin is significantly increased in failing myocardium (con indicates control). B and C, Vinculin localization using confocal microscopy. B, In normal myocardium, labeling at the intercalated disk, at the costameres, and in the T-tubular system is evident. C, In failing myocardium, vinculin fluorescence is more abundant and disorganized. Red in panel C indicates lipofuscin granules.
In the confocal microscope, vinculin showed a distinct localization at the intercalated disks and at the lateral sarcolemma in normal myocardium. This localization was more intense in failing hearts, corresponding to the results from Western blotting (Figure 5B⇑).
Fibronectin
The mRNA for fibronectin was 5-fold increased as compared with controls (Figure 6A⇓); the protein was increased 2.9-fold (Figure 6B⇓).
Fibronectin is significantly increased by Northern (A) and Western (B) blot analysis (con indicates control). C and D, Confocal images of fibronectin (green) and actin (red) labeling. E and F, Colocalization of fibronectin (red) and vinculin (green). C, Normal myocardium shows fibronectin as a fine line surrounding the myocytes and capillary vessels. D, In failing myocardium, the interstitial space is enlarged and fibronectin is significantly increased, leading to encapsulation of myocytes. E, In this slightly tangential section, vinculin is present at the intercalated disk, at the lateral sarcolemma, and in the T system. F, At high magnification of the boxed area from panel E, the close spatial localization of fibronectin and vinculin at the T-tubular membrane and the sarcolemma is evident (arrows). Myocytes are unstained (black).
In immunolabeling, it was evident that fibronectin was present in the extracellular space and in the basement membrane of myocytes, smooth muscle cells, and endothelial cells (Figure 6C⇑). The expression was more intense in the widened interstitial space of failing hearts (Figure 6D⇑). A close colocalization of fibronectin and vinculin was shown by double labeling (Figures 6E⇑ and 6F⇑)
Vimentin
The mRNA for vimentin was upregulated 1.7-fold as compared with controls (Figure 7A⇓), and the protein was increased 1.5-fold in patients with heart failure (Figure 7B⇓).
Vimentin is significantly increased on the mRNA (A) and protein (B) levels (con indicates control). C and D, Confocal images of immunofluorescence for vimentin (red), with myocytes counterstained with phalloidin (green). C, Normal myocardium with few fibroblasts and capillaries. D, In failing myocardium, the myocytes are separated by fibrotic material containing many fibroblasts. Only few capillaries are visible. Red in myocytes indicates lipofuscin granules.
Immunostaining of normal myocardium showed that vimentin was present in fibroblasts and endothelial cells (Figure 7C⇑). In failing hearts, fibroblasts were more numerous, corresponding to the values from Western blot (Figure 7D⇑).
Discussion
This study demonstrates for the first time significant changes of cytoskeletal and membrane-associated proteins in human hearts failing because of longstanding DCM. We show that tubulin and desmin are significantly increased, not only at the protein level but also at the mRNA level. The same is true for vinculin, fibronectin, and vimentin. In the confocal microscope, a distinct disorganization and accumulation of the microtubules and desmin filaments were evident, which supports the quantitative protein data. A good correlation was found between protein content and LVEDP in controls and patients with DCM. It is hypothesized, therefore, that not only the loss of myofilaments as described previously2 3 but also the increase in cytoskeletal and membrane-associated proteins may play a major role in the pathogenesis of contractile and diastolic dysfunction in failing hearts.4
The role of the cytoskeleton as a stabilizing factor of cellular structure and functional integrity is well established.20 Tubulin is organized around the nucleus and in the longitudinal direction of the cell, and it contributes to the stability of the contractile apparatus in relation to the nucleus, mitochondria, and cellular membrane.21 Tubulin turnover is continuous and high and is an energy-consuming process. Therefore, it is especially interesting that a ubiquitous accumulation of tubulin takes place in failing hearts. It cannot be excluded at the present time that tubulin synthesis plays a significant role in the transition from hypertrophy to the decompensated state in the human heart, as shown in rats with developing hypertrophy due to aortic banding.22
The concept of microtubular involvement in contractile and diastolic dysfunction in failing hearts, previously formulated by Tsutsui et al6 7 and Tagawa et al11 in hearts with decompensated hypertrophy, is supported and extended to the involvement of other proteins by the data in human hearts presented here. Cellular hypertrophy as present in experimental animals was also found in our patients.23 One significant difference between both models, however, is the fact that in the animal experiments the contractile machinery was intact, indicating that the more chronic situation in the human heart represents a unique pathophysiological entity. The present data suggest that similarities develop in the final structural as well as functional deterioration in failing hearts independently of the cause of failure. It may be concluded that changes, not only of tubulin, as reported by Tsutsui et al6 7 and Tagawa et al,11 but also of desmin and other linkage proteins, in addition to the loss of myofilaments and the occurrence of fibrosis, are the structural correlate of the reduction of ejection fraction and the increase in LVEDP as observed in our patients.
Desmin connects the sarcomeres in the transverse direction, thereby inhibiting slippage during contraction. Desmin accumulation and disorganization were especially evident in cells lacking contractile material. Given that desmin is localized around Z-lines and that it connects neighboring sarcomeres, this disorganization can be explained by the absence of a structural element with which it can be associated. Using desmin knockout mice, Capetanaki et al24 showed that desmin is essential for the maintenance of the functional integrity of myofibrils, whole myofibers, and the general cellular integrity, which was confirmed in mice with desmin null mutations in which degeneration of cardiac muscle was observed.25 The findings of the present study are in agreement with those reported in congenital myopathies and hereditary cardiac diseases.26 27 28 Therefore, the desmin augmentation found in human myocardium was interpreted as a compensatory mechanism to ensure cellular integrity and sarcomere stability.
Vinculin, a member of the family of membrane-associated proteins, is situated at the costameres of the lateral sarcolemma and at the intercalated disk19 and is one of the major components of the linkage system that connects via the integrins the intracellular milieu with the extracellular matrix.29 30 31 The β1-integrins act as receptors for fibronectin. Their dynamic interaction with both the cytoskeleton and fibronectin is important for structural changes during muscle cell differentiation (see Reference 32 for other relevant references).
We report here that vinculin was increased at the protein level. In another study, we found that dystrophin, talin, and spectrin were increased as well.21 This indicates that the entire group of membrane-associated proteins is involved in the attempt to stabilize the sarcolemma and its connections to the contractile apparatus on the one hand and to the extracellular matrix on the other hand. The stabilizing function of the cytoskeleton is of importance when the contractile material of the cardiomyocytes is reduced as a result of the progression from hypertrophy to failure. In the early stages of the disease, therefore, this might help the cardiomyocytes to maintain function and may be regarded as a compensatory mechanism. Recent experimental studies have shown that a dystrophin missense mutation in the mouse,33 muscle LIM protein (MLP) deficiency in mice,34 or cleavage of dystrophin by enteroviral proteases35 result in the clinical picture of DCM. On the basis of these data, the hypothesis was put forward that DCM is a disease of cytoskeletal damage.36 37 This view, however, is in contradistinction to the increased density of the major cytoskeletal components in human hearts with DCM as reported here.
Fibronectin is the major extracellular matrix protein and is an important component of the cellular basement membrane.38 It is increased in hearts with DCM, resulting, together with an increase of other extracellular proteins, in a significant degree of fibrosis.4 39 Vimentin, the intermediate filament of fibroblasts and endothelial cells, was studied because it represents an indicator of the cellularity of the interstitium.40 It was significantly elevated because the number of fibroblasts was higher than in control. Taken together, these findings indicate that the synthesis of connective tissue components is continuous and will result in progressive fibrosis despite pretransplantation treatment of all patients with angiotensin-converting enzyme inhibitors. In an experimental study, we have recently shown that fibrosis development cannot be prevented indefinitely by this treatment,41 which would confirm the data presented here. Fibrosis will contribute to an increased stiffness and loss of ventricular compliance.42
The cytoskeleton also plays an important role in mechanotransduction across the cell surface, where integrins act as mechanoreceptors.43 Transfer of force from integrins to the cytoskeleton is thought to represent a proximal step in intracellular mechanical signaling that leads to global cytoskeletal rearrangements.43 Furthermore, it has been shown that the extracellular matrix controls cytoskeletal mechanics and structure, particularly by binding of fibronectin to integrins.44 45 Interestingly, increasing extracellular matrix contacts by binding through an elevated number of integrins increases cytoskeletal stiffness and apparent viscosity.44 Transferring these data to our own findings, it may be assumed that the increased content of fibronectin found in failing hearts is the inducer of changes of cytoskeletal structure and function.
The question remains open whether the changes described here are effects rather than causes of heart failure. The present data, however, are more in support of the hypothesis that these structural changes are contributory to the transition to heart failure. This hypothesis will be tested in human hearts with compensatory hypertrophy. Another question is whether the cytoskeletal proteins either have a structural role only or participate in cellular signaling. As discussed recently, “chronic increases in wall stress mediated by cytoskeletal pathways” (page 558) as is the case in failing hearts with DCM, may play a decisive role in cellular hypertrophy and cell survival.46 Recent evidence concerning α- or δ-sarcoglycan47 or LIM domain protein34 –deficient mice strongly suggests that the cytoskeleton might be involved in cellular signaling.
In conclusion, in myocytes from failing human hearts, the major components of the cytoskeleton tubulin and desmin, as well as the membrane-associated protein vinculin, are increased, most probably as a mechanism compensatory for the loss of contractile filaments, thereby contributing to an increased stiffness of individual cardiomyocytes. Furthermore, the linkage protein vinculin and the extracellular matrix protein fibronectin are augmented, which will, by interaction with the integrins, further increase cellular stiffness. Fibronectin and vimentin indicate a progressive development of fibrosis. The present data support experimental reports showing the important role of microtubule accumulation in failing hearts. They furthermore show that changes of a whole complex of proteins, in addition to the loss of contractile filaments and proteins of the sarcomeric skeleton described previously,3 represent the structural basis for the reduction of contractile function and compliance in failing human hearts.21
Acknowledgments
We thank Gunther Schuster for computer assistance.
- Received October 12, 1999.
- Accepted February 25, 2000.
- © 2000 American Heart Association, Inc.
References
- ↵
Braunwald E. Pathophysiology of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders Co Inc; 1980:453–483.
- ↵
- ↵
Schaper J, Froede R, Hein S, Buck A, Hashizume H, Speiser B, Friedl A, Bleese N. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation. 1991;83:504–514.
- ↵
Schaper J, Speiser B, Brand T. The cytoskeleton and extracellular matrix in human hearts with dilated cardiomyopathy. In: Figulla HR, Kandolf R, McManus B, eds. Idiopathic Dilated Cardiomyopathy. Berlin, Germany: Springer-Verlag; 1993:75–80.
- ↵
Grossman W, Jones D, McLaurin MP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56–64.
- ↵
Tsutsui H, Ishihara K, Cooper G. Cytoskeletal role for contractile dysfunction of hypertrophied myocardium. Science. 1993;260:682–687.
- ↵
Tsutsui H, Tagawa H, Kent RL, McCollam PL, Ishihara K, Nagatsu M, Cooper G. Role of microtubules in contractile dysfunction of hypertrophied cardiocytes. Circulation. 1994;90:533–555.
- ↵
Tagawa H, Koide M, Sato H, Zile MR, Carabello BA, Cooper G. Cytoskeletal role in the transition from compensated to decompensated hypertrophy during adult canine left ventricular pressure overloading. Circ Res. 1998;82:751–761.
- ↵
- ↵
Tagawa H, Rozich JD, Tsutsui H, Narishige T, Kuppuswamy D, Sato H, McDermott PJ, Koide M, Cooper G. Basis for increased microtubules in pressure-hypertrophied cardiocytes. Circulation. 1996;93:1230–1243.
- ↵
Tagawa H, Wang N, Narishige T, Ingber DE, Zile MR, Cooper G. Cytoskeletal mechanics in pressure-overload cardiac hypertrophy. Circ Res. 1997;80:281–289.
- ↵
Sato II, Nagai T, Kuppuswamy D, Narishige T, Koide M, Menick DR, Cooper G. Microtubule stabilization in pressure overload cardiac hypertrophy. J Cell Biol. 1997;139:963–973.
- ↵
Watson PA, Hannan R, Carl LL, Giger KE. Contractile activity and passive strength regulate tubulin mRNA and protein content in cardiac myocytes. Am J Physiol. 1996;271(2 pt 1):C684–C689.
- ↵
- ↵
- ↵
- ↵
de Tombe PP. Altered contractile function in heart failure. Cardiovasc Res. 1998;37:367–380.
- ↵
- ↵
- ↵
- ↵
- ↵
Watkins SC, Samuel JL, Marotte F, Bertier-Savalle B, Rappaport L. Microtubules and desmin filaments during onset of heart hypertrophy in the rat: a double immunoelectron microscope study. Circ Res. 1987;60:327–336.
- ↵
- ↵
- ↵
Milner DJ, Weitzer G, Tran D, Bradley A, Capetanaki Y. Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol. 1996;134:1255–1270.
- ↵
Thornell LE, Johanson B, Erikson A, Lehto VP, Virtanen I. Intermediate filament and associated proteins in the human heart: an immunofluorescence study of normal and pathological hearts. Eur Heart J. 1984;5(suppl F):231–241.
- ↵
Thornell LE, Price MG. The cytoskeleton in muscle cells in relation to function. Biochem Soc Transact. 1991;19:1116–1120.
- ↵
- ↵
Geiger B. Vinculin, an intracellular protein localized at specialized sites where microfilaments bundles terminate at cell membranes. Proc Natl Acad Sci U S A. 1980;77:4127–4131.
- ↵
- ↵
Pardo JV, Siliciano J, Craig SW. Vinculin is a component of an extensive network of myofibril-sarcolemma attachment regions in cardiac muscle fibers. J Cell Biol. 1983;97:1081–1088.
- ↵
- ↵
Ortiz-Lopez R, Hua L, Su J, Goytia V, Towbin JA. Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. Circulation. 1997;95:2434–2440.
- ↵
Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard J-C, Chien KR, Caroni P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1987;88:393–403.
- ↵
- ↵
- ↵
- ↵
Hynes RO. Fibronectins. Berlin, Germany: Springer; 1989.
- ↵
- ↵
Traub P. Intermediate Filaments: A Review. Berlin, Germany: Springer-Verlag; 1985.
- ↵
- ↵
Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27:341–348.
- ↵
Wang N, Butler JP, Ingber DE. Mechanotransduction across the cell surface and through the cytoskeleton. Science. 1993;260:1124–1127.
- ↵
- ↵
- ↵
- ↵
Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, Davisson RL, Straub V, Barresi R, Bansal D, Hrstka RF, Williamson R, Campbell K. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell. 1999;98:465–474.
This Issue
Jump to
Article Tools
- Increased Expression of Cytoskeletal, Linkage, and Extracellular Proteins in Failing Human MyocardiumAnnette Heling, René Zimmermann, Sawa Kostin, Yoshi Maeno, Stefan Hein, Bruno Devaux, Erwin Bauer, Wolf-Peter Klövekorn, Martin Schlepper, Wolfgang Schaper and Jutta SchaperCirculation Research. 2000;86:846-853, originally published April 28, 2000https://doi.org/10.1161/01.RES.86.8.846
Citation Manager Formats
Share this Article
- Increased Expression of Cytoskeletal, Linkage, and Extracellular Proteins in Failing Human MyocardiumAnnette Heling, René Zimmermann, Sawa Kostin, Yoshi Maeno, Stefan Hein, Bruno Devaux, Erwin Bauer, Wolf-Peter Klövekorn, Martin Schlepper, Wolfgang Schaper and Jutta SchaperCirculation Research. 2000;86:846-853, originally published April 28, 2000https://doi.org/10.1161/01.RES.86.8.846